The strong Phase 2a data and strategic refocus on izicopan suggest upcoming catalysts in HS and potentially AAV; watch for Phase 2b trial design clarity from FDA and partnership signals. The extended cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
InflaRx reported financial results for 2025, highlighted by a narrow improvement in net loss to €45.6M from €46.1M in 2024, alongside strong Phase 2a data for izicopan in hidradenitis suppurativa and chronic spontaneous urticaria. The company is pivoting to focus on izicopan as a 'pipeline-in-a-product' while scaling back GOHIBIC commercial activities, preserving €46.2M in cash to fund operations into mid-2027.
Key Financial Metrics
Key Facts
- Positive Phase 2a data for izicopan in HS and CSU showed rapid, meaningful clinical improvements with no safety concerns.
- Company is focusing entirely on izicopan, discontinuing GOHIBIC commercial spending in the U.S. and writing down €4.0M in inventory.
- Net loss improved to €45.6M in 2025 from €46.1M in 2024; R&D expenses dropped 27% YoY to €25.7M.
- Cash, cash equivalents, and marketable securities totaled €46.2M as of December 31, 2025, funding operations into mid-2027.
- Plans for a PK bridging study in China and a virtual Capital Markets Day this spring to detail izicopan's development path.
Financial Impact
Reduced R&D and commercial spending led to lower net loss and improved cash efficiency; €33.3M raised via financing in 2025.
Risk Factors
- izicopan remains in early development; Phase 2b and later trials may not replicate Phase 2a results.
- Heavy reliance on a single asset (izicopan) increases binary risk.
- Market cap of $52M may not fully reflect development risk in a highly competitive immunology space.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258900 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.56 (−0.00%) |
Oct 22, 2026 4d ago | Press Release | $1.53 | awaiting T+20 | — | $1.56 (+1.96%) |
Oct 2, 2026 24d ago | Press Release | $1.72 | awaiting T+20 | — | $1.56 (−9.30%) |
Oct 1, 2026 25d ago | Press Release | $1.71 | awaiting T+20 | — | $1.56 (−8.77%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.56 (+24.64%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.56 (+22.39%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.56 (−9.30%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.56 (−33.05%) |
Jun 30, 2026 16w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.56 (−30.36%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.56 (+41.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers